{"custom_id": "samples_table_GSE277168.csv", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o-mini", "messages": [{"role": "system", "content": "You are an expert in analyzing clinical datasets for inclusion in a meta-analysis on adjuvant chemotherapy (ACT) in NSCLC (non-small cell lung cancer). Your task is to determine whether the provided dataset includes relevant adjuvant chemotherapy (ACT) data for inclusion in the meta-dataset."}, {"role": "user", "content": "The dataset below contains clinical and treatment information for NSCLC patients. You are provided with the first 10 patients and their covariates. Your task is to answer the following:\n\nQuestions:\n1. Should it be included?\n\n\"GPL13497_Group,GPL13497_Accession,GPL13497_Title,GPL13497_Source name,GPL13497_Disease,GPL13497_Cell line,GPL13497_Genotype,GPL13497_Treatment,FTP_Group,FTP_Accession,FTP_Title,FTP_Source name,FTP_Disease,FTP_Cell line,FTP_Genotype,FTP_Treatment\\n-,GSM8515732,A549Lsub ctr_1,A549Lsub ctr,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,ctr,-,GSM8515732,A549Lsub ctr_1,A549Lsub ctr,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,ctr\\n-,GSM8515733,A549Lsub ctr_2,A549Lsub ctr,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,ctr,-,GSM8515733,A549Lsub ctr_2,A549Lsub ctr,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,ctr\\n-,GSM8515734,A549Lsub ctr_3,A549Lsub ctr,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,ctr,-,GSM8515734,A549Lsub ctr_3,A549Lsub ctr,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,ctr\\n-,GSM8515735,A549Lsub+TGFb_1,A549Lsub+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,TGFb,-,GSM8515735,A549Lsub+TGFb_1,A549Lsub+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,TGFb\\n-,GSM8515736,A549Lsub+TGFb_2,A549Lsub+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,TGFb,-,GSM8515736,A549Lsub+TGFb_2,A549Lsub+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,TGFb\\n-,GSM8515737,A549Lsub+TGFb_3,A549Lsub+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,TGFb,-,GSM8515737,A549Lsub+TGFb_3,A549Lsub+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,Lsub,TGFb\\n-,GSM8515738,A549WT+TGFb_1,A549WT+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,TGFb,-,GSM8515738,A549WT+TGFb_1,A549WT+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,TGFb\\n-,GSM8515739,A549WT+TGFb_2,A549WT+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,TGFb,-,GSM8515739,A549WT+TGFb_2,A549WT+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,TGFb\\n-,GSM8515740,A549WT+TGFb_3,A549WT+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,TGFb,-,GSM8515740,A549WT+TGFb_3,A549WT+TGFb,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,TGFb\\n-,GSM8515741,A549WT_ctr_1,A549WT,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,ctr,-,GSM8515741,A549WT_ctr_1,A549WT,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,ctr\\n-,GSM8515742,A549WT_ctr_2,A549WT,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,ctr,-,GSM8515742,A549WT_ctr_2,A549WT,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,ctr\\n-,GSM8515743,A549WT_ctr_3,A549WT,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,ctr,-,GSM8515743,A549WT_ctr_3,A549WT,non-small cell lung cancer,A549 adenocarcinoma cell line,WT,ctr\\n\""}], "temperature": 0}}
{"custom_id": "samples_table_GSE271130.csv", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o-mini", "messages": [{"role": "system", "content": "You are an expert in analyzing clinical datasets for inclusion in a meta-analysis on adjuvant chemotherapy (ACT) in NSCLC (non-small cell lung cancer). Your task is to determine whether the provided dataset includes relevant adjuvant chemotherapy (ACT) data for inclusion in the meta-dataset."}, {"role": "user", "content": "The dataset below contains clinical and treatment information for NSCLC patients. You are provided with the first 10 patients and their covariates. Your task is to answer the following:\n\nQuestions:\n1. Should it be included?\n\n\"GPL23159_Group,GPL23159_Accession,GPL23159_Title,GPL23159_Source name,GPL23159_Tumor type,GPL23159_Tissue,GPL23159_Cell line,FTP_Group,FTP_Accession,FTP_Title,FTP_Source name,FTP_Tumor type,FTP_Tissue,FTP_Cell line\\n-,GSM8370224,H2023_CTRL mimic_A,H2023 transfected with mimic control,adenocarcinoma,Lung,NCI-H2023,-,GSM8370224,H2023_CTRL mimic_A,H2023 transfected with mimic control,adenocarcinoma,Lung,NCI-H2023\\n-,GSM8370225,H2023_ mimic miR29a_A,H2023 transfected with mimic miR-29a-3p,adenocarcinoma,Lung,NCI-H2023,-,GSM8370225,H2023_ mimic miR29a_A,H2023 transfected with mimic miR-29a-3p,adenocarcinoma,Lung,NCI-H2023\\n-,GSM8370226,H2023_ mimic miR223_A,H2023 transfected with mimic miR-223-3p,adenocarcinoma,Lung,NCI-H2023,-,GSM8370226,H2023_ mimic miR223_A,H2023 transfected with mimic miR-223-3p,adenocarcinoma,Lung,NCI-H2023\\n-,GSM8370227,H2023_CTRL mimic_B,H2023 transfected with mimic control,adenocarcinoma,Lung,NCI-H2023,-,GSM8370227,H2023_CTRL mimic_B,H2023 transfected with mimic control,adenocarcinoma,Lung,NCI-H2023\\n-,GSM8370228,H2023_ mimic miR29a_B,H2023 transfected with mimic miR-29a-3p,adenocarcinoma,Lung,NCI-H2023,-,GSM8370228,H2023_ mimic miR29a_B,H2023 transfected with mimic miR-29a-3p,adenocarcinoma,Lung,NCI-H2023\\n-,GSM8370229,H2023_ mimic miR223_B,H2023 transfected with mimic miR-223-3p,adenocarcinoma,Lung,NCI-H2023,-,GSM8370229,H2023_ mimic miR223_B,H2023 transfected with mimic miR-223-3p,adenocarcinoma,Lung,NCI-H2023\\n\""}], "temperature": 0}}
{"custom_id": "samples_table_GSE296415.csv", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o-mini", "messages": [{"role": "system", "content": "You are an expert in analyzing clinical datasets for inclusion in a meta-analysis on adjuvant chemotherapy (ACT) in NSCLC (non-small cell lung cancer). Your task is to determine whether the provided dataset includes relevant adjuvant chemotherapy (ACT) data for inclusion in the meta-dataset."}, {"role": "user", "content": "The dataset below contains clinical and treatment information for NSCLC patients. You are provided with the first 10 patients and their covariates. Your task is to answer the following:\n\nQuestions:\n1. Should it be included?\n\n\"GPL21825_Group,GPL21825_Accession,GPL21825_Title,GPL21825_Source name,GPL21825_Age,GPL21825_Gender,GPL21825_Stage,FTP_Group,FTP_Accession,FTP_Title,FTP_Source name,FTP_Age,FTP_Gender,FTP_Stage\\n-,GSM8970073,circRNA Microarray Service for 8 human samples_2,plasma from lung adenocarcinoma patient,53,female,T1bN0M0 IA,-,GSM8970073,circRNA Microarray Service for 8 human samples_2,plasma from lung adenocarcinoma patient,53,female,T1bN0M0 IA\\n-,GSM8970074,circRNA Microarray Service for 8 human samples_3,plasma from lung adenocarcinoma patient,60,male,T1cN0M0 IA,-,GSM8970074,circRNA Microarray Service for 8 human samples_3,plasma from lung adenocarcinoma patient,60,male,T1cN0M0 IA\\n-,GSM8970075,circRNA Microarray Service for 8 human samples_4,plasma from healthy control,40,female,,-,GSM8970075,circRNA Microarray Service for 8 human samples_4,plasma from healthy control,40,female,\\n-,GSM8970076,circRNA Microarray Service for 8 human samples_5,plasma from healthy control,45,female,,-,GSM8970076,circRNA Microarray Service for 8 human samples_5,plasma from healthy control,45,female,\\n-,GSM8970077,circRNA Microarray Service for 8 human samples_6,plasma from healthy control,41,female,,-,GSM8970077,circRNA Microarray Service for 8 human samples_6,plasma from healthy control,41,female,\\n-,GSM8970078,circRNA Microarray Service for 8 human samples_42,plasma from lung adenocarcinoma patient,59,male,T2N0M0 IIA,-,GSM8970078,circRNA Microarray Service for 8 human samples_42,plasma from lung adenocarcinoma patient,59,male,T2N0M0 IIA\\n-,GSM8970079,circRNA Microarray Service for 8 human samples_44,plasma from healthy control,41,male,,-,GSM8970079,circRNA Microarray Service for 8 human samples_44,plasma from healthy control,41,male,\\n-,GSM8970080,circRNA Microarray Service for 8 human samples_48,plasma from lung adenocarcinoma patient,56,female,T1bN0M0 IA,-,GSM8970080,circRNA Microarray Service for 8 human samples_48,plasma from lung adenocarcinoma patient,56,female,T1bN0M0 IA\\n\""}], "temperature": 0}}
{"custom_id": "samples_table_GSE202417.csv", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o-mini", "messages": [{"role": "system", "content": "You are an expert in analyzing clinical datasets for inclusion in a meta-analysis on adjuvant chemotherapy (ACT) in NSCLC (non-small cell lung cancer). Your task is to determine whether the provided dataset includes relevant adjuvant chemotherapy (ACT) data for inclusion in the meta-dataset."}, {"role": "user", "content": "The dataset below contains clinical and treatment information for NSCLC patients. You are provided with the first 10 patients and their covariates. Your task is to answer the following:\n\nQuestions:\n1. Should it be included?\n\n\"GPL23126_Group,GPL23126_Accession,GPL23126_Title,GPL23126_Source name,GPL23126_Tissue,GPL23126_Cell type,GPL23126_Phenotype,GPL23126_Treatment,GPL23126_Time,FTP_Group,FTP_Accession,FTP_Title,FTP_Source name,FTP_Tissue,FTP_Cell type,FTP_Phenotype,FTP_Treatment,FTP_Time\\n-,GSM6122161,Combo1-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment,-,GSM6122161,Combo1-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment\\n-,GSM6122162,Combo1-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment,-,GSM6122162,Combo1-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment\\n-,GSM6122163,Combo2-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment,-,GSM6122163,Combo2-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment\\n-,GSM6122164,Combo2-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment,-,GSM6122164,Combo2-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment\\n-,GSM6122165,Combo6-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment,-,GSM6122165,Combo6-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment\\n-,GSM6122166,Combo6-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment,-,GSM6122166,Combo6-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment\\n-,GSM6122167,Combo8-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment,-,GSM6122167,Combo8-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment\\n-,GSM6122168,Combo8-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment,-,GSM6122168,Combo8-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment\\n-,GSM6122169,Combo9-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment,-,GSM6122169,Combo9-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment\\n-,GSM6122170,Combo9-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment,-,GSM6122170,Combo9-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment\\n-,GSM6122171,Combo10-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment,-,GSM6122171,Combo10-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment\\n-,GSM6122172,Combo10-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment,-,GSM6122172,Combo10-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment\\n-,GSM6122173,Combo11-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment,-,GSM6122173,Combo11-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment\\n-,GSM6122174,Combo11-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment,-,GSM6122174,Combo11-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment\\n-,GSM6122175,Combo12-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment,-,GSM6122175,Combo12-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment\\n-,GSM6122176,Combo12-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment,-,GSM6122176,Combo12-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment\\n-,GSM6122177,Combo13-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment,-,GSM6122177,Combo13-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment\\n-,GSM6122178,Combo13-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment,-,GSM6122178,Combo13-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment\\n-,GSM6122179,Combo14-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment,-,GSM6122179,Combo14-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment\\n-,GSM6122180,Combo14-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment,-,GSM6122180,Combo14-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment\\n-,GSM6122181,Combo15-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment,-,GSM6122181,Combo15-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment\\n-,GSM6122182,Combo15-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment,-,GSM6122182,Combo15-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment\\n-,GSM6122183,Combo16-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment,-,GSM6122183,Combo16-R-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,untreated,pre-treatment\\n-,GSM6122184,Combo16-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment,-,GSM6122184,Combo16-R-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,R,nivolumab and bezafibrate,post-treatment\\n-,GSM6122185,Combo17-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment,-,GSM6122185,Combo17-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment\\n-,GSM6122186,Combo17-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment,-,GSM6122186,Combo17-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment\\n-,GSM6122187,Combo18-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment,-,GSM6122187,Combo18-NR-1,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,untreated,pre-treatment\\n-,GSM6122188,Combo18-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment,-,GSM6122188,Combo18-NR-2,\\\"Peripheral blood, CD8+ sorted\\\",Blood,PBMC CD8+T cells,NR,nivolumab and bezafibrate,post-treatment\\n\""}], "temperature": 0}}
{"custom_id": "samples_table_GSE179192.csv", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o-mini", "messages": [{"role": "system", "content": "You are an expert in analyzing clinical datasets for inclusion in a meta-analysis on adjuvant chemotherapy (ACT) in NSCLC (non-small cell lung cancer). Your task is to determine whether the provided dataset includes relevant adjuvant chemotherapy (ACT) data for inclusion in the meta-dataset."}, {"role": "user", "content": "The dataset below contains clinical and treatment information for NSCLC patients. You are provided with the first 10 patients and their covariates. Your task is to answer the following:\n\nQuestions:\n1. Should it be included?\n\n\"GPL21185_Group,GPL21185_Accession,GPL21185_Title,GPL21185_Source name,GPL21185_Treatment,GPL21185_Cell line,FTP_Group,FTP_Accession,FTP_Title,FTP_Source name,FTP_Treatment,FTP_Cell line\\n-,GSM5411274,PC9_Control_1,Untreated control PC9 cell line,Control,PC9,-,GSM5411274,PC9_Control_1,Untreated control PC9 cell line,Control,PC9\\n-,GSM5411275,PC9_Control_2,Untreated control PC9 cell line,Control,PC9,-,GSM5411275,PC9_Control_2,Untreated control PC9 cell line,Control,PC9\\n-,GSM5411276,PC9_Control_3,Untreated control PC9 cell line,Control,PC9,-,GSM5411276,PC9_Control_3,Untreated control PC9 cell line,Control,PC9\\n-,GSM5411277,PC9-SORA-1d-1,Sorafenib-treated (1 day) PC9 cell line,Sorafenib - 1 day,PC9,-,GSM5411277,PC9-SORA-1d-1,Sorafenib-treated (1 day) PC9 cell line,Sorafenib - 1 day,PC9\\n-,GSM5411278,PC9-SORA-1d-2,Sorafenib-treated (1 day) PC9 cell line,Sorafenib - 1 day,PC9,-,GSM5411278,PC9-SORA-1d-2,Sorafenib-treated (1 day) PC9 cell line,Sorafenib - 1 day,PC9\\n-,GSM5411279,PC9-SORA-1d-3,Sorafenib-treated (1 day) PC9 cell line,Sorafenib - 1 day,PC9,-,GSM5411279,PC9-SORA-1d-3,Sorafenib-treated (1 day) PC9 cell line,Sorafenib - 1 day,PC9\\n-,GSM5411280,PC9-SORA-2d-1,Sorafenib-treated (2 days) PC9 cell line,Sorafenib - 2 days,PC9,-,GSM5411280,PC9-SORA-2d-1,Sorafenib-treated (2 days) PC9 cell line,Sorafenib - 2 days,PC9\\n-,GSM5411281,PC9-SORA-2d-2,Sorafenib-treated (2 days) PC9 cell line,Sorafenib - 2 days,PC9,-,GSM5411281,PC9-SORA-2d-2,Sorafenib-treated (2 days) PC9 cell line,Sorafenib - 2 days,PC9\\n-,GSM5411282,PC9-SORA-2d-3,Sorafenib-treated (2 days) PC9 cell line,Sorafenib - 2 days,PC9,-,GSM5411282,PC9-SORA-2d-3,Sorafenib-treated (2 days) PC9 cell line,Sorafenib - 2 days,PC9\\n-,GSM5411283,PC9-SORA-4d-1,Sorafenib-treated (4 day) PC9 cell line,Sorafenib - 4 days,PC9,-,GSM5411283,PC9-SORA-4d-1,Sorafenib-treated (4 day) PC9 cell line,Sorafenib - 4 days,PC9\\n-,GSM5411284,PC9-SORA-4d-2,Sorafenib-treated (4 day) PC9 cell line,Sorafenib - 4 days,PC9,-,GSM5411284,PC9-SORA-4d-2,Sorafenib-treated (4 day) PC9 cell line,Sorafenib - 4 days,PC9\\n-,GSM5411285,PC9-SORA-4d-3,Sorafenib-treated (4 day) PC9 cell line,Sorafenib - 4 days,PC9,-,GSM5411285,PC9-SORA-4d-3,Sorafenib-treated (4 day) PC9 cell line,Sorafenib - 4 days,PC9\\n-,GSM5411286,PC9-OSIM-1d-1,Osimertinib-treated (1 day) PC9 cell line,Osimertinib - 1 day,PC9,-,GSM5411286,PC9-OSIM-1d-1,Osimertinib-treated (1 day) PC9 cell line,Osimertinib - 1 day,PC9\\n-,GSM5411287,PC9-OSIM-1d-2,Osimertinib-treated (1 day) PC9 cell line,Osimertinib - 1 day,PC9,-,GSM5411287,PC9-OSIM-1d-2,Osimertinib-treated (1 day) PC9 cell line,Osimertinib - 1 day,PC9\\n-,GSM5411288,PC9-OSIM-1d-3,Osimertinib-treated (1 day) PC9 cell line,Osimertinib - 1 day,PC9,-,GSM5411288,PC9-OSIM-1d-3,Osimertinib-treated (1 day) PC9 cell line,Osimertinib - 1 day,PC9\\n-,GSM5411289,PC9-OSIM-2d-1,Osimertinib-treated (2 days) PC9 cell line,Osimertinib - 2 days,PC9,-,GSM5411289,PC9-OSIM-2d-1,Osimertinib-treated (2 days) PC9 cell line,Osimertinib - 2 days,PC9\\n-,GSM5411290,PC9-OSIM-2d-2,Osimertinib-treated (2 days) PC9 cell line,Osimertinib - 2 days,PC9,-,GSM5411290,PC9-OSIM-2d-2,Osimertinib-treated (2 days) PC9 cell line,Osimertinib - 2 days,PC9\\n-,GSM5411291,PC9-OSIM-2d-3,Osimertinib-treated (2 days) PC9 cell line,Osimertinib - 2 days,PC9,-,GSM5411291,PC9-OSIM-2d-3,Osimertinib-treated (2 days) PC9 cell line,Osimertinib - 2 days,PC9\\n-,GSM5411292,PC9-OSIM-4d-1,Osimertinib-treated (4 days) PC9 cell line,Osimertinib - 4 days,PC9,-,GSM5411292,PC9-OSIM-4d-1,Osimertinib-treated (4 days) PC9 cell line,Osimertinib - 4 days,PC9\\n-,GSM5411293,PC9-OSIM-4d-2,Osimertinib-treated (4 days) PC9 cell line,Osimertinib - 4 days,PC9,-,GSM5411293,PC9-OSIM-4d-2,Osimertinib-treated (4 days) PC9 cell line,Osimertinib - 4 days,PC9\\n-,GSM5411294,PC9-OSIM-4d-3,Osimertinib-treated (4 days) PC9 cell line,Osimertinib - 4 days,PC9,-,GSM5411294,PC9-OSIM-4d-3,Osimertinib-treated (4 days) PC9 cell line,Osimertinib - 4 days,PC9\\n-,GSM5411295,PC9-SORA-OSIM-2d-1,Sorafenib and Osimertinib co-treated (2 days) PC9 cell line,Sorafenib and Osimertinib - 2 days,PC9,-,GSM5411295,PC9-SORA-OSIM-2d-1,Sorafenib and Osimertinib co-treated (2 days) PC9 cell line,Sorafenib and Osimertinib - 2 days,PC9\\n-,GSM5411296,PC9-SORA-OSIM-2d-2,Sorafenib and Osimertinib co-treated (2 days) PC9 cell line,Sorafenib and Osimertinib - 2 days,PC9,-,GSM5411296,PC9-SORA-OSIM-2d-2,Sorafenib and Osimertinib co-treated (2 days) PC9 cell line,Sorafenib and Osimertinib - 2 days,PC9\\n-,GSM5411297,PC9-SORA-OSIM-2d-3,Sorafenib and Osimertinib co-treated (2 days) PC9 cell line,Sorafenib and Osimertinib - 2 days,PC9,-,GSM5411297,PC9-SORA-OSIM-2d-3,Sorafenib and Osimertinib co-treated (2 days) PC9 cell line,Sorafenib and Osimertinib - 2 days,PC9\\n\""}], "temperature": 0}}
